Skip to main content
SpringerLink
Log in

Kommentar zu den neuen Leitlinien (2016) der European Society of Cardiology und European Atherosclerosis Society zur Diagnostik und Therapie der Dyslipidämien

Comments on the new guidelines (2016) of the European Society of Cardiology and the European Atherosclerosis Society on the diagnostics and treatment of dyslipidemias

  • Leitlinien
  • Published:
Der Kardiologe Aims and scope

Zusammenfassung

Dyslipidämien, insbesondere das Low-density-Lipoprotein (LDL), sind kausal an der Entstehung und klinischen Progression atherosklerotischer Gefäßerkrankungen wie der koronaren Herzerkrankung beteiligt und sind deshalb ein wichtiges Therapieziel in der Prävention von kardiovaskulären Ereignissen wie Herzinfarkt und Schlaganfall. Die neue Leitlinie der European Society of Cardiology (ESC) und der European Atherosclerosis Society (EAS) fokussiert insbesondere auf eine effiziente Kontrolle des LDL-Cholesterins mit risikoabhängigen Zielwerten, weil hier aktuell am besten eine effiziente Risikoreduktion erreicht werden kann. Bei Patienten mit sehr hohem kardiovaskulärem Risiko wird neben dem LDL-Cholesterin-Zielwert < 70 mg/dl auch eine > 50 % Reduktion des LDL-Cholesterins empfohlen, wenn der Ausgangs-LDL-C < 140 mg/dl liegt. Hier möchten wir weitere für die klinische Praxis wichtige Aspekte der neuen Leitlinie diskutieren.

Abstract

Dyslipidemias, in particular low-density lipoprotein (LDL), play a causal role in the development and clinical progression of atherosclerotic cardiovascular diseases, such as coronary disease and are therefore an important therapeutic target for prevention of myocardial infarction and stroke. The novel guidelines from the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) focus in particular on an efficient control of LDL-cholesterol (LDL‑C) with risk-dependent treatment targets. In patients with very high cardiovascular risk besides the LDL‑C target < 70 mg/dl a >50% reduction of LDL‑C is recommended in patients with an initial LDL-C < 140 mg/dl. Here we discuss further important aspects relevant to clinical practice in these novel guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Catapano AL et al (2016) ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37(39):2999–3058

    Article  PubMed  Google Scholar 

  2. European Association for Cardiovascular et al (2011) ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32(14):1769–1818

    Article  Google Scholar 

  3. Emerging Risk Factors C et al (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302(18):1993–2000

    Article  Google Scholar 

  4. Piepoli MF et al (2016) European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37(29):2315–2381

    Article  PubMed  Google Scholar 

  5. Nordestgaard BG et al (2016) Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 37(25):1944–1958

    Article  PubMed  PubMed Central  Google Scholar 

  6. Jorgensen AB et al (2013) Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 34(24):1826–1833

    Article  CAS  PubMed  Google Scholar 

  7. Kolovou GD et al (2011) Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 9(3):258–270

    Article  CAS  PubMed  Google Scholar 

  8. Mihas C et al (2011) Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. Curr Vasc Pharmacol 9(3):271–280

    Article  CAS  PubMed  Google Scholar 

  9. Nordestgaard BG, Varbo A (2014) Triglycerides and cardiovascular disease. Lancet 384(9943):626–635

    Article  CAS  PubMed  Google Scholar 

  10. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG (2014) Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 63(5):470–477

    Article  CAS  PubMed  Google Scholar 

  11. Kronenberg F, Utermann G (2013) Lipoprotein(a): resurrected by genetics. J Intern Med 273(1):6–30

    Article  CAS  PubMed  Google Scholar 

  12. Nordestgaard BG et al (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31(23):2844–2853

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Nordestgaard BG et al (2013) Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34(45):3478–390a

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Stone NJ et al (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl 2):S1–S45

    Article  PubMed  Google Scholar 

  15. Writing C et al (2016) 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol 68(1):92–125

    Article  Google Scholar 

  16. Cholesterol Treatment Trialists et al (2015) Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385(9976):1397–1405

    Article  Google Scholar 

  17. Cholesterol Treatment Trialists, Cholesterol Treatment Trialists (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380(9841):581–590

    Article  Google Scholar 

  18. Cannon CP et al (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372(25):2387–2397

    Article  CAS  PubMed  Google Scholar 

  19. Boekholdt SM et al (2014) Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 64(5):485–494

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Weng TC et al (2010) A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 35(2):139–151

    Article  CAS  PubMed  Google Scholar 

  21. Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326(7404):1423

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Parker BA et al (2013) Effect of statins on skeletal muscle function. Circulation 127(1):96–103

    Article  CAS  PubMed  Google Scholar 

  23. Landmesser U et al (2016) ESC/EAS consensus statement on PCSK9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J. doi:10.1093/eurheartj/ehw480

  24. Lyseng-Williamson KA (2012) Ezetimibe/simvastatin: a guide to its clinical use in hypercholesterolemia. Am J Cardiovasc Drugs 12(1):49–56

    Article  CAS  PubMed  Google Scholar 

  25. Sudhop T et al (2002) Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106(15):1943–1948

    Article  CAS  PubMed  Google Scholar 

  26. Norata GD, Tibolla G, Catapano AL (2014) Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol 54:273–293

    Article  CAS  PubMed  Google Scholar 

  27. Koren MJ et al (2014) Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 63(23):2531–2540

    Article  CAS  PubMed  Google Scholar 

  28. Roth EM, McKenney JM (2015) ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiol 11(1):27–37

    Article  CAS  PubMed  Google Scholar 

  29. Robinson JG et al (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1489–1499

    Article  CAS  PubMed  Google Scholar 

  30. Sabatine MS et al (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1500–1509

    Article  CAS  PubMed  Google Scholar 

  31. Navarese EP et al (2016) Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review. Ann Intern Med 164(9):600–607

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Kardiologie, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Deutschland

    U. Landmesser

  2. Ballrechten-Dottingen, Deutschland

    H. Gohlke

  3. Klinikum Links der Weser, Bremen, Deutschland

    R. Hambrecht

  4. Klinik für Kardiologie, Pneumologie und Angiologie, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland

    M. Kelm

  5. Klinik für Kardiologie, Angiologie und internistische Intensivmedizin, Universitätsklinikum des Saarlands, Homburg, Deutschland

    U. Laufs

  6. Klinik für Kardiologie, Angiologie, Pneumologie und internistische Intensivmedizin, Universitätsklinikum Aachen, Aachen, Deutschland

    N. Marx

Authors
  1. U. Landmesser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Gohlke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Hambrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Kelm
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U. Laufs
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. Marx
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U. Landmesser.

Ethics declarations

Interessenkonflikt

Den Interessenkonflikt der Autoren finden Sie online auf der DGK-Homepage unter http://leitlinien.dgk.org/ bei der entsprechenden Publikation.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Malte Kelm für die Kommission für Klinische Kardiovaskuläre Medizin der DGK.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Landmesser, U., Gohlke, H., Hambrecht, R. et al. Kommentar zu den neuen Leitlinien (2016) der European Society of Cardiology und European Atherosclerosis Society zur Diagnostik und Therapie der Dyslipidämien. Kardiologe 11, 295–299 (2017). https://doi.org/10.1007/s12181-017-0166-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-017-0166-9

Schlüsselwörter

Keywords

Search

Navigation